Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01362010 | Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients | PHASE2 | COMPLETED | 150 | — | — | Jan 1, 2012 | Jul 1, 2013 | Aug 15, 2013 | 3 | Israel |
The change in lesion count (inflammatory, non-inflammatory, and total) after 12 weeks of treatment compared to baseline
Physician's Global Improvement Assessment
| Arm | Type | Description |
|---|---|---|
| Topical Minocycline Foam FXFM244 - 4% | EXPERIMENTAL | Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening. |
| Topical Minocycline Foam FXFM244 - 1% | EXPERIMENTAL | Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening. |
| Placebo foam | PLACEBO_COMPARATOR | Active ingredient: None Route: Topical Dosage schedule: Once daily, evening |
| Name | Type | Description |
|---|---|---|
| Topical Minocycline Foam FXFM244 | DRUG | Topically applied once a day. |
Inclusion Criteria: * A clinical diagnosis of Acne Vulgaris with facial involvement. * A minimum of 20 but not more than 50 inflammatory lesions on the face (papules and/ or pustules). * A minimum of 25 but not more than 100 non-inflammatory lesions on the face (opened and/or closed comedones). * N...